The current portfolio of available oral drugs to treat T2D is comprised of multiple drug classes targeting the different elements of the disease pathogenesis by reducing hepatic gluconeogenesis, indirectly and directly promoting insulin secretion, promoting renal glucose excretion, and improving peripheral insulin resistance.21 This evidence concerns the gene INS and Insulin resistance.